TY - JOUR
T1 - Micropollutant point sources in the built environment: identification and monitoring of priority pharmaceutical substances in hospital effluents
AU - Helwig, Karin
AU - Hunter, Colin
AU - MacLachlan, John
AU - McNaughtan, Moyra
AU - Roberts, Joanne
AU - Cornelissen, Alex
AU - Dagot, Christophe
AU - Evenblij, Herman
AU - Klepiszewski, Kai
AU - Sven, Lyko
AU - Nafo, Issa
AU - McArdell, Christa
AU - Pahl, Ole
N1 - Duplicate entry deleted 25-4-18 (created by KHE)
PY - 2013/7
Y1 - 2013/7
N2 - A method is described for the identification of priority micropollutants (pharmaceuticals) in the aquatic environment originating from hospitals. The lack of data on the range and volume of prescribed pharmaceuticals, and on their behaviour in the environment, presented a considerable challenge to the initial selection process. The final selection of pharmaceutical substances to be included in the monitoring campaigns was based on literature data, existing priority lists, national consumption patterns and expert input from within the regions (Northwest Europe). Fifteen micropollutant compounds were identified from the diverse range of reported and prescribed pharmaceuticals in the healthcare sector:atenolol, carbamazepine, diclofenac, naproxen, lidocaine, ifosphamide, cyclophosphamide, ciprofloxacin, erythromycin, clarithromycin, sulfamethoxazole, iopromide, iopamidol, diatrizoate, and bezafibrate. Eight hospital locations in six countries were monitored for periods ranging from several weeks to one year.
AB - A method is described for the identification of priority micropollutants (pharmaceuticals) in the aquatic environment originating from hospitals. The lack of data on the range and volume of prescribed pharmaceuticals, and on their behaviour in the environment, presented a considerable challenge to the initial selection process. The final selection of pharmaceutical substances to be included in the monitoring campaigns was based on literature data, existing priority lists, national consumption patterns and expert input from within the regions (Northwest Europe). Fifteen micropollutant compounds were identified from the diverse range of reported and prescribed pharmaceuticals in the healthcare sector:atenolol, carbamazepine, diclofenac, naproxen, lidocaine, ifosphamide, cyclophosphamide, ciprofloxacin, erythromycin, clarithromycin, sulfamethoxazole, iopromide, iopamidol, diatrizoate, and bezafibrate. Eight hospital locations in six countries were monitored for periods ranging from several weeks to one year.
KW - pharmaceuticals
KW - micropollutants
KW - point sources
KW - hospitals
KW - prioritisation
KW - environmental monitoring
U2 - 10.4172/2161-0525.1000177
DO - 10.4172/2161-0525.1000177
M3 - Article
VL - 3
SP - 1
EP - 10
JO - Journal of Environmental & Analytical Toxicology
JF - Journal of Environmental & Analytical Toxicology
SN - 2161-0525
IS - 4
ER -